TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06168786
Drug: Cadonilimab
Normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cadonilimab:10mg/kg, ivgtt, d1, q3w
Study: NCT00000718
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000718
Drug: Zalcitabine
Normalized name: Zalcitabine
DrugBank: Zalcitabine (DB00943)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04715932
Drug: Hesperidin
Normalized name: Hesperidin
DrugBank: Hesperidin (DB04703)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive study medication Hesperidin and will take 2 capsules of 500mg at the same time in the evening, at bedtime with water.
Study: NCT05219084
Drug: hip denervation
Normalized name: HIP
DrugBank: Heme iron polypeptide (DB11067)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 2% 2ml was injected into each genicular nerve
Study: NCT00440960
Drug: propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00440960
Drug: midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00440960
Drug: alfentanil
Normalized name: Alfentanil
DrugBank: Alfentanil (DB00802)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00440960
Drug: lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04689919
Drug: Rivaroxaban 20 MG Oral Tablet
Normalized name: rivaroxaban 20 MG Oral Tablet
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The subjects randomly received single oral dose of Rivaroxaban 20 MG Tablet.
Study: NCT05939635
Drug: IV morphine patient-controlled analgesia (PCA)
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine will be administered via PCA device for the first 24 hours after surgery
Study: NCT00006199
Drug: Topotecan
Normalized name: Topotecan
DrugBank: Topotecan (DB01030)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00476983
Drug: saquinavir/ritonavir plus truvada
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: SQV/r 1500/100 mg OD + Truvada OD for 2 years
Study: NCT04923776
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The dosage for this drug is area under the curve (AUC) 5 mg/ml/min intravenous, Day 1, every 21 days for 4 cycles. This is standard of care.
Study: NCT04923776
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The dosage for this drug is 100 mg/m2 Intravenous, Days 1-3, every 21 days for 4 cycles. This is standard of care.
Study: NCT04923776
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The dosage for this drug is 1200 mg Intravenous, Day 1, every 21 days until disease progression. This is standard of care.
Study: NCT05943821
Drug: Allopurinol 200 mg
Normalized name: allopurinol 200 MG
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The intervention will occur after randomly allocating participants to the first group (G1), in which patients will receive allopurinol at an initial daily dose of 200 mg, or to the second group (G2), where they will receive a placebo. The placebo will be prepared as tablets with the same shape and appearance as the tested drug tablets, in the appropriate doses, and containing the same excipients. Participants will initially take one tablet of the medication daily in the morning. The physicians will dispense the drugs in packs of 30 tablets for the entire interval between visits (therapy 26 weeks ± 2 weeks). The patients will receive the medications during visit V1. The drugs will be prepared in identical packages, appropriately sealed, with a number for drug identification.
Study: NCT02036723
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive bevacizumab at a dose 1.25 mg (in 0.05 ml of solution) as an intravitreal injection on day 1 and then every 28 days during 12 months.
Study: NCT02036723
Drug: Ranibizumab
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will receive ranibizumab at a dose 0.50 mg (in 0.05 ml of solution) as an intravitreal injection on day 1 and then every 28 days during 12 months.
Study: NCT00000964
Drug: Ranitidine hydrochloride
Normalized name: Ranitidine Hydrochloride
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000964
Drug: Foscarnet sodium
Normalized name: Foscarnet Sodium
DrugBank: Foscarnet (DB00529)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04008628
Drug: Nitrous Oxide
Normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhalation of a 50%/50% nitrous oxide/oxygen mixture (Kalinox®)
Study: NCT05363514
Drug: Low Dose Naltrexone
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participant takes Low Dose Naltrexone 4.5mg PO OD for 120 days. Participant will complete a a 4 week titration to target dose of 4.5mg. Week 1-2: 1.5mg PO OD. Week 3-4: 3.0mg PO OD. Week 5-16: 4.5mg PO OD. Participant will be provided with masked capsules in blister packs.
Study: NCT05363514
Drug: Microcrystalline cellulose
Normalized name: Microcrystalline Cellulose
DrugBank: Microcrystalline cellulose (DB14158)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participant takes microcrystalline cellulose 4.5mg PO OD for 120 days. Participant will complete a a 4 week titration to target dose of 4.5mg. Week 1-2: 1.5mg PO OD. Week 3-4: 3.0mg PO OD. Week 5-16: 4.5mg PO OD. Participant will be provided with masked capsules in blister packs.
Study: NCT04060316
Drug: GLS-1200
Normalized name: GL-2045
DrugBank: GL-2045 (DB16971)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLS-1200 is given as a nasal spray using an atomizer
Study: NCT05919316
Drug: Nasonex Nasal Spray
Normalized name: mometasone Metered Dose Nasal Spray [Nasonex]
DrugBank: Mometasone (DB00764)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50mcg/dose, 2 sprays each nostril (morning or evening) once daily for 14 days
Study: NCT06299852
Drug: Trastuzumab emtansine
Normalized name: Trastuzumab emtansine
DrugBank: Trastuzumab emtansine (DB05773)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: SRT for metastatic foci
Study: NCT06399809
Drug: Fisetin
Normalized name: FISETIN
DrugBank: Fisetin (DB07795)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fisetin is a flavanol, present in strawberries, apples, and persimmons, that destroys senescent cells (i.e. a senolytic therapy). Of three senolytic therapies being tested in clinical trials, fisetin has the best safety profile.
Study: NCT05009680
Drug: GB1211
Normalized name: GB1211
DrugBank: GB1211 (DB17499)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GB1211 is a galectin-3 inhibitor an orally available small molecule anti-fibrotic. It is administered orally twice a day
Study: NCT05608980
Drug: 0.01% hypochlorous acid
DrugBank: Hypochlorous acid (DB14135)
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily 0.01% hypochlorous acid topical treatment via ultrasonic atomization for 2 weeks
Study: NCT04720131
Drug: Camrelizumab
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camrelizumab was administered 200mg iv every 3 weeks.
Study: NCT04720131
Drug: apatinib
Normalized name: Apatinib
DrugBank: Rivoceranib (DB14765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib A safety-run-in was conducted in the first cycle to identify the recommended dose of Apatinib, the initial dose was administered 250mg orally daily every 3 weeks (Day 1-14 of a treatment cycle) The dose of Apatinib increase and reduction was 250 mg orally q.d. and 250 mg orally q.o.d. every 3 weeks respectively according to the number of doses limiting toxicity events (DLTs) in the initial group.~The final dose of Apatinib for the extension stage was detemained by the result of safety-run-in stage.
Study: NCT03877991
Drug: CBD-sesame oil capsule
Normalized name: Sesame Oil
DrugBank: Sesame oil (DB11172)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A capsule containing cannabidiol dissolved in sesame oil and surfactant vehicle.
Study: NCT06633718
Drug: Meropenem and Pralurbactam
Normalized name: meropenem and vaborbactam
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3g，q8h，120min infusion
Study: NCT06633718
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100mL，q8h，60min infusion
Study: NCT06633718
Drug: Ceftazidime-avibactam
Normalized name: avibactam
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2.5g，q8h，120min infusion
Study: NCT06633718
Drug: Metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.915g，q8h，60min infusion
Study: NCT04842565
Drug: Sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintilimab (200mg ivdrip D1 Q3W)
Study: NCT05903456
Drug: lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ronvastinib is an orally administered multi-receptor tyrosine kinase (RTK) inhibitor that selectively inhibits the kinase activity of vascular endothelial growth factor (VEGF) receptors, such as VEGF-1, VEGF-2, and VEGF-3, in addition to inhibiting other pro-angiogenic and oncogenic signaling pathways associated with tumor proliferation ，has been approved as a first-line treatment for liver cancer
Study: NCT05903456
Drug: Icaritin soft capsules
Normalized name: Icaritin
DrugBank: Icaritin (DB12672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Icaritin soft capsule is a flavonoid compound extracted from traditional Chinese medicinal materials. It is a new type of small molecule immunomodulator. It is a 1.2 class of innovative Chinese medicine with global independent intellectual property rights. By inhibiting inflammatory signaling pathway and reducing the release of inflammatory factors, the immune microenvironment can be regulated to play an anti-tumor role. At present, it has been approved for first-line treatment of advanced liver cancer, with good efficacy and safety.
Study: NCT04602715
Drug: MET-2
Normalized name: Met
DrugBank: Methionine (DB00134)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will take capsules containing MET-2 daily during the trial. There will be a loading dose at the start of dosing, and a daily dose. There will be a booster dose given at week 2 and a second booster dose taken at week 4 for those subjects who have not improved by that time.
Study: NCT06632561
Drug: Empagliflozin 10 mg
Normalized name: empagliflozin 10 MG
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Empagliflozin (a sodium-glucose cotransporter-2 inhibitor) 10 mg one tablet daily dose for 6 months
Study: NCT05873712
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT05873712
Drug: Zanubrutinib
Normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Given PO
Study: NCT00006267
Drug: rubitecan
Normalized name: Rubitecan
DrugBank: Rubitecan (DB06159)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06457958
Drug: Sevoflurane Group
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative: One hour before surgery, a blood sample will be taken. Intraoperative: Sevoflurane will be used as the inhalational anesthetic. Routine general anesthesia procedures will be followed. Sevoflurane consumption, oxygen levels, and vital parameters will be recorded.~Postoperative: One hour after extubation, another blood sample will be taken, marking the end of patient monitoring.~Laboratory Analysis: Blood samples will be stored in the biochemistry laboratory. Hemoxygenase-1 protein levels will be measured by ELISA, and mRNA expression will be analyzed using PCR.
Study: NCT04758975
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: VENETOCLAX: Ramp-up than 400 mg QD
Study: NCT04758975
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: RITUXIMAB: Cycle 7 Day 1 375 mg/m2; Cycles 8-12 Day 1 500 mg/m2
Study: NCT04758975
Drug: Ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IBRUTINIB 420 mg QD
Study: NCT05490485
Drug: Camrelizumab
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camrelizumab combined with cisplatin for advanced cutaneous squamous cell carcinoma
Study: NCT04467801
Drug: Ipatasertib
Normalized name: Ipatasertib
DrugBank: Ipatasertib (DB11743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipatasertib is a novel ATP-competitive inhibitor. It is taken by mouth once daily.
Study: NCT06361979
Drug: SHR-A1811
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-A1811: intravenous
Study: NCT06361979
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab:intravenous
Study: NCT06457958
Drug: Desflurane Group
Normalized name: Desflurane
DrugBank: Desflurane (DB01189)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative: One hour before surgery, a blood sample will be taken. Intraoperative: Desflurane will be used as the inhalational anesthetic. Routine general anesthesia procedures will be followed. Desflurane consumption, oxygen levels, and vital parameters will be recorded.~Postoperative: One hour after extubation, another blood sample will be taken, marking the end of patient monitoring.~Laboratory Analysis: Blood samples will be stored in the biochemistry laboratory. Hemoxygenase-1 protein levels will be measured by ELISA, and mRNA expression will be analyzed using PCR.
Study: NCT06374758
Drug: bictegravir/emtricitabine/tenofovir alafenamide 50/200/25 mg
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Same as above, it is the same intervetion
Study: NCT04521582
Drug: Amlodipine
Normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The facility-based community health worker will receive protocol-driven training to initiate amlodipine for hypertensive patients. These patients will receive lifestyle counseling by Female Community Health Volunteer through home visits (5 times \[including baseline and end of the study\] in the active municipality and 3 times \[including baseline and end of the study\] in the control municipality).
Study: NCT05241028
Drug: Ensartinib
Normalized name: Ensartinib
DrugBank: Ensartinib (DB14860)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ensartinib 225mg oral daily for 3 years or until recurrence of the disease or intolerable toxicity
Study: NCT04913805
Drug: Potassium Nitrate
Normalized name: Potassium Nitrate
DrugBank: Potassium citrate (DB09125)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Potassium Nitrate is the active intervention that may increase blood flow to exercising muscle
Study: NCT00496535
Drug: TNFerade biologic
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06240520
Drug: Panobinostat 20 MG Oral Capsule
Normalized name: panobinostat 20 MG Oral Capsule
DrugBank: Panobinostat (DB06603)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Panobinostat 20mg will be administered once orally
Study: NCT06240520
Drug: Pyrimethamine 200mg Oral Tablet
Normalized name: Pyrimethamine
DrugBank: Pyrimethamine (DB00205)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pyrimethamine 200mg will be administered once orally
Study: NCT06240520
Drug: Lenalidomide 25 MG Oral Capsule
Normalized name: Lenalidomide 25 mg oral capsule
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lenalidomide 25mg will be administered once orally
Study: NCT04220931
Drug: botulinum toxin injection
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type B (DB00042)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: injection of Botulinum toxin A 100 UI, single dose administration, in the major papilla, in the Oddi sphincter, during upper gastrointestinal endoscopy.
Study: NCT04808466
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel is used as drug for hyperthermic intraperitoneal chemotherapy. Choice of perfusate: Normal saline. Drug selection and dose: Paclitaxel 75 mg/m2 . Treatment course: 2 times (the first time is after surgery, the second time is 48h after first time).
Study: NCT04808466
Drug: Lobaplatin
Normalized name: Lobaplatin
DrugBank: Lobaplatin (DB13049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lobaplatin is used as drug for hyperthermic intraperitoneal chemotherapy. Choice of perfusate: Normal saline. Drug selection and dose: lobaplatin 50 mg/m2 . Treatment course: 2 times (the first time is after surgery, the second time is 48h after first time).
Study: NCT05644600
Drug: Nintedanib
Normalized name: Nintedanib
DrugBank: Nintedanib (DB09079)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The subjects will be administered Nintedanib soft capsules single oral dose in the morning of Day 1 in fasted state.
Study: NCT05366764
Drug: Salbutamol or levosalbutamol
Normalized name: Medicated Pad or Tape
DrugBank: Levosalbutamol (DB13139)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: metered dose inhaler
Study: NCT06273839
Drug: Tafamidis 61 mg free acid tablet (Test 1)
Normalized name: tafamidis 61 MG
DrugBank: Tafamidis (DB11644)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tafamidis 61 mg free acid tablet (Test 1)
Study: NCT06273839
Drug: Tafamidis 70 mg free acid tablet (Test 1)
DrugBank: Tafamidis (DB11644)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tafamidis 61 mg free acid tablet (Test 1)
Study: NCT06273839
Drug: Tafamidis 61 mg free acid capsule (Reference)
Normalized name: tafamidis 61 MG
DrugBank: Tafamidis (DB11644)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tafamidis 61 mg free acid capsule (Reference)
Study: NCT05994001
Drug: LM-302
Normalized name: LM-030
DrugBank: LM-030 (DB18283)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LM-302 :ClAUDIN 18.2-ADC
Study: NCT05522985
Drug: Triprilimab combined with TP
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Both interventions all drugs intravenous infusion, D1, once every 3 weeks, a total of 3 cycles.
Study: NCT04576156
Drug: Imetelstat
Normalized name: Imetelstat
DrugBank: Imetelstat (DB14909)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imetelstat sodium will be given intravenously at 9.4 mg/kg every 21 days, until disease progression or unacceptable toxicity, treatment discontinuation or study end.
Study: NCT05494645
Drug: Exparel
Normalized name: Exparel
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal bupivicaine
Study: NCT05494645
Drug: Peripheral Nerve Block
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peripheral nerve block without Exparel
Study: NCT04565925
Drug: Sildenafil Citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil 20mg TID for 4 weeks
Study: NCT06117878
Drug: NK510
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: NK510 will be administered through intravenous infusion.once a week，for a total of six times.
Study: NCT06117878
Drug: NK510
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: NK510 will be administered through intravenous infusion.Twice infusions on week 1,week 3,week 5 respectively.
Study: NCT05210374
Drug: Copper Gluconate
Normalized name: Copper Gluconate
DrugBank: Copper gluconate (DB11246)
Approvals — FDA: no, EMA: no, PMDA: no
Description: To be taken orally (PO), 5.2mg/m2/day daily in the PM, rounded~for pill size (max 9mg/day) To be administered day 1-7~Lead-in week and day 1-28 cycles Cycle length: 28~days, maximum 12 cycles
Study: NCT05951855
Drug: Selinexor
Normalized name: Selinexor
DrugBank: Selinexor (DB11942)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Selinexor 60mg/day, weight≥70kg (40mg/day, weight\<70kg) orally on d1,4,8,11,
Study: NCT05951855
Drug: Chidamide
Normalized name: Chidamide
DrugBank: Tucidinostat (DB06334)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Chidamide 10mg/day, orally on day 1 to 28
Study: NCT06344936
Drug: HRS-1780 tablets; Itraconazole capsules; Rifampicin capsules
DrugBank: Itraconazole (DB01167)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment PartⅠ: Itraconazole capsule, 200mg QD, 7 times; HRS-1780 tablets, 10mg QD, twice Treatment PartⅡ: Rifampicin capsules, 600mg QD, 14 times; HRS-1780 tablets, 10mg QD, twice
Study: NCT04474990
Drug: Tradipitant
Normalized name: Tradipitant
DrugBank: Tradipitant (DB12580)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NK-1 Receptor antagonist
Study: NCT04889287
Drug: Elinzanetant (BAY3427080)
Normalized name: Elinzanetant
DrugBank: Elinzanetant (DB18968)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily over 12 days
Study: NCT04475835
Drug: Bivalirudin
Normalized name: Bivalirudin
DrugBank: Bivalirudin (DB00006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bivaliruding 0.75 mg/kg intravenous bolus loading dose, and immediately followed by intravenous infusion of 1.75 mg/kg/h until 4 hours after PCI. A prolonged infusion of 0.2 mg/kg/h for ≤20h could be considered at the operator's discretion. It is recommended that ACT be monitored 5 minutes after the first administration, and if ACT is \<225 s (Hemotec method), intravenous injection of 0.30 mg/kg of bivalirudin should be administered.
Study: NCT06132932
Drug: WX390
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will receive WX390 1.1 mg tablet orally once a day for a continuous 28-day cycle.
Study: NCT04300140
Drug: Batiraxcept
Normalized name: Batiraxcept
DrugBank: Batiraxcept (DB17522)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Batiraxcept is experimental drug
Study: NCT04300140
Drug: Cabozantinib (Cabo)
DrugBank: Cabozantinib (DB08875)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cabozantinib is standard of care as monotherapy and in combination with nivolumab in ccRCC
Study: NCT04300140
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab is standard of care in the first line treatment of ccRCC